newsfilter
← Latest News
GlobeNewswire·

BeyondSpring Reports First‑Quarter 2025 Financial Results and Provides Corporate Update

Presentation at IO 360° conference showed early efficacy for Plinabulin combinations in metastatic NSCLC and Hodgkin lymphoma resistant to PD‑1/L1 therapySEED's first‑in‑class RBM39 degrader, reported at AACR 2025 for